Draft Minutes
MSSNY’S Addiction and Psychiatric Medicine Committee
Friday, October 14, 2016
8:30 a.m. – 10:00 a.m.
Via Web conference and Teleconference

Present
Edmond Amyot, MD, Chair
Glenn Martin, MD
Tzvi Furer, MD
Lynn Hohmann, MD
Nina Huberman, MD
Katherine McCarthy, MD
Marvin Rabinowitz, MD
Norman Wetterau, MD

MSSNY Staff
Pat Clancy, VP, Public Health & Education
Terri Holmes, Secretary

Absent
Jose David, MD
Brian Johnson, MD
Ammar Kassem El Sara, MD
Darvin Varon, MD
Stephen Wade, MD

Excused
Frank Dowling, MD, Commissioner
Stephen Hermele, MD
Jeffrey Selzer, MD

1) Welcome/Introductions: The meeting was called to order.

2) Adoption of Minutes: May 20, 2016 Change date from January 22, 2016 to May 20, 2016 and add Glenn Martin, MD to Present list. Minutes were adopted.

3) Behavioral Health - DSRIP: It was stated that the state is very committed to the integration of behavioral health and physical health services. There are complex state and federal regulations. The state has done a lot to modify regulations so that the integration can happen. This is a very confusing and complex issue and also situation and circumstance specific to individual locations. It was suggested that someone be invited to the next meeting for more clarification on this issue. Dr. Hohmann agreed to share both a link and the names of some people who may be able to help with clarification.

4) 2017 Sunset Report Recommendations:

65.994 Dextromethorphan Abuse in Adolescents:
MSSNY supports regulation and/or legislation which would mandate policy that dextromethorphan-containing products be placed behind pharmacy counters to prevent abuse in adolescents. (HOD 2007-150)

RECOMMENDATION: REAFFIRM WITH MODIFICATION. Since 2013, New York prohibits pharmacies and stores from selling Dextromethorphan, found in over-the-counter cold medications, to minors unless they have a prescription. Under the law, all retail establishments selling DXM will be required to request proof of age unless the customer appears to be more than 25 years of age. Any retailer violating the new prohibition will be subject to a fine of $250 for each violation. A number of counties in the state including Nassau and Suffolk have already enacted a restriction on the retail sale of DXM to individuals age 18 years and younger. The modification was presented to update the policy to support law.
Medical Use of Marijuana/Synthetic Cannabinoids:
MSSNY will encourage additional research on the use of cannabinoid products in the treatment of illness and the relief of human suffering without penalty, and acknowledge the AMA Report, Medical Marijuana (A-01), as updated February 2007. (HOD 2007-151)

RECOMMENDATION: REAFFIRM WITH MODIFICATION. This policy is still germane, and the modification was to delete the reference to the 2007 AMA report on Medical Marijuana.

5) Medical Marijuana Draft Regulations: The governor’s office came out with a series of recommendations for expanding the medical marijuana program in allowing Nurse Practitioners to certify patients. DOH has proposed regulations to incorporate the provisions that the governor made recommendations for. Committee members expressed grave concerns with NP’s being added to the list. The Medical Society has not taken a position on this issue.

6) Safe Injections Facilities Discussion: There is a movement in NYC for the establishment of Supervised Injection Facilities. There is a coalition that has formed. There is serious interest in this concept. Assemblywoman Rosenthal was considering legislation at the end of the last session. Many members expressed support of the concept. This could provide someplace safe which would reduce the Infectious Diseases component. Also, it’s an access sight for treatment. It was agreed that someone from the Harm Reduction Coalition be invited to the next meeting for a brief presentation on this issue.

7) Informational Items:
   a) HHS Opioid Package
   b) CARA – Sign on Letter: The Comprehensive Addiction & Recovery Act was passed by congress. MSSNY did sign in support of the letter with the understanding that there would be significant monies attached during the budgetary process to implement the program. On October 28, 2017 Patricia Harris, AMA Chairman of the Board will be presenting to the Bioethics Committee. Ms. Clancy invited the Addiction & Psychiatric Medicine Committee to take part in the call.
   c) Kratom – Federal Action: The DEA was going to move Kratom to schedule 2 but they are not reconsidering their position.

8) 2017 Meeting Dates: February 10, 2017; May 5, 2017 and October 27, 2017